Search results
Results from the WOW.Com Content Network
An article published by the journal Nature on 6 July 2021 cited data released by the United Arab Emirates on some 81,000 individuals who had received Sputnik V, according to which the vaccine demonstrated an efficacy of 97.8% in preventing symptomatic COVID-19, and 100% efficacy in preventing severe complications.
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [6] As of September 2021, no study on Sputnik Light reported confidence intervals, so it is not possible to know the accuracy of the estimates. Effectiveness is generally expected to slowly decrease over time. [7]
In addition, vaccine developers have been criticized for aggressively advertising their vaccine efficacy prior to the completion of phase III clinical trial. The most substantial criticism came from Dr. Konstantin Chumakov, who currently serves as the associate director for Research at the FDA Office of Vaccines Research and Review.
A shingles vaccine may contain a surprising benefit Research from Oxford University suggests that the shingles vaccine, Shingrix, might delay the onset of dementia by five to nine months.
On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the Delta variant. [81] On July 21, researchers from PHE published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from Delta after 2 doses, while the Astrazeneca vaccine was 67% ...
Vaccines from AstraZeneca , Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual ...
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study. The co-administration ...
The head of the Russian Direct Investment Fund (RDIF) stated that 20 countries had requested in total 1 billion doses of the vaccine, nicknamed Sputnik V. [11] On August 20 registration was called "conditional" with final registration depends on results of Phase 3 trial, [12] such registration is limited and allowed by Decree 441 for medicines ...